About Silence Therapeutics
Silence Therapeutics is a company based in London (United Kingdom) founded in 1999. The company has 116 employees as of December 31, 2024. Silence Therapeutics has completed 1 acquisition, including Intradigm Corporation. Silence Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter London, United Kingdom
- Employees 116 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Silence Therapeutics, Plc.
-
Annual Revenue
$42.35 M (USD)30.7as on Dec 31, 2024
-
Net Profit
-$44.36 M (USD)20.12as on Dec 31, 2024
-
EBITDA
-$47.96 M (USD)9.6as on Dec 31, 2024
-
Latest Funding Round
$120 M (USD), Post-IPO
May 25, 2021
-
Investors
Astrazeneca
& 5 more
-
Employee Count
116
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Silence Therapeutics
Silence Therapeutics is a publicly listed company on the OTC with ticker symbol SLNCF in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Silence Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Silence Therapeutics
Investors in Silence Therapeutics
Silence Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Mallinckrodt Pharmaceuticals and Adage Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Private equity firm focused on company buyouts
|
Locked | Locked | Locked |
Investor details for Silence Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Silence Therapeutics
Silence Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Intradigm Corporation.
Investment portfolio details for Silence Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops RNA interference (RNAi) therapeutics for the treatment of cancer.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Silence Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Silence Therapeutics
Detailed financials for Silence Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Silence Therapeutics Comparisons
Peer comparison for Silence Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Silence Therapeutics
Silence Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Silence Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Silence Therapeutics
Complete news archive for Silence Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Silence Therapeutics
Silence Therapeutics was founded in 1999 and raised its 1st funding round 10 years after it was founded.
Silence Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
As of Dec 31, 2024, the latest employee count at Silence Therapeutics is 116.
Annual revenue of Silence Therapeutics is $42.35M as on Dec 31, 2024.
Founded in 1999 and headquartered in London, United Kingdom, RNA therapeutics are developed by the company for hematology and cardiovascular diseases. The pipeline features gene silencing approaches, including one that targets the Lipoprotein(A) gene to reduce risks of heart disease and stroke, and another that silences the TMPRSS6 gene to regulate iron levels in the body. Operations focus on advancing these treatments through clinical development.
Silence Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Yes, Silence Therapeutics is publicly traded on OTC under the ticker symbol SLNCF.
Silence Therapeutics has made 1 acquisition, including Intradigm Corporation.
Silence Therapeutics has 6 investors. Key investors include Astrazeneca, Mallinckrodt Pharmaceuticals, Adage Capital Management, BVF Partners, and Consonance Capital.
The ticker symbol of Silence Therapeutics is SLNCF on OTC.